Nirmatrelvir combined with ritonavir for preventing and treating COVID-19-Reference-Cited by-同舟云学术

Nirmatrelvir combined with ritonavir for preventing and treating COVID-19

Published:2023-11-30 Issue:11 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Reis Stefanie¹,Metzendorf Maria-Inti²,Kuehn Rebecca³,Popp Maria¹,Gagyor Ildiko⁴,Kranke Peter¹,Meybohm Patrick¹,Skoetz Nicole⁵,Weibel Stephanie¹

Affiliation:

1. Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine; University Hospital Würzburg; Würzburg Germany

2. Cochrane Metabolic and Endocrine Disorders Group; Institute of General Practice, Medical Faculty of the Heinrich-Heine University Düsseldorf; Düsseldorf Germany

3. Department of Clinical Sciences; Liverpool School of Tropical Medicine; Liverpool UK

4. Department of General Practice; University Hospital Würzburg; Würzburg Germany

5. Cochrane Haematology, Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne; Center for Integrated Oncology, University of Cologne; Cologne Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference184 articles.

1. An interventional efficacy and safety, Phase 2/3, double-blind, 2-arm study to investigate orally administered PF-07321332/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002895-38

2. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits;Hammond;Open Forum Infectious Diseases,2022

3. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo;Hammond;Open Forum Infectious Diseases,2022

4. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19;Hammond;New England Journal of Medicine,2022

5. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 clinicaltrials.gov/ct2/show/NCT04960202

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial;Frontiers in Pharmacology;2024-05-27